Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) started the day on Thursday, with a price decrease of -1.00% at $1.98, before settling in for the price of $2.00 at the close. Taking a more long-term approach, AMLX posted a 52-week range of $1.98-$31.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 2300.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -328.33%. This publicly-traded company’s shares outstanding now amounts to $67.71 million, simultaneously with a float of $47.57 million. The organization now has a market capitalization sitting at $134.20 million. At the time of writing, stock’s 50-day Moving Average stood at $8.80, while the 200-day Moving Average is $15.54.
Amylyx Pharmaceuticals Inc (AMLX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Amylyx Pharmaceuticals Inc’s current insider ownership accounts for 29.83%, in contrast to 89.48% institutional ownership. According to the most recent insider trade that took place on Mar 05 ’24, this organization’s Co-Chief Executive Officer sold 4,135 shares at the rate of 18.73, making the entire transaction reach 77,440 in total value, affecting insider ownership by 2,959,308. Preceding that transaction, on Mar 05 ’24, Company’s Co-Chief Executive Officer sold 4,135 for 18.73, making the whole transaction’s value amount to 77,440. This particular insider is now the holder of 3,023,002 in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.62 per share during the current fiscal year.
Amylyx Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -328.33% and is forecasted to reach -1.32 in the upcoming year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Let’s observe the current performance indicators for Amylyx Pharmaceuticals Inc (AMLX). It’s Quick Ratio in the last reported quarter now stands at 5.20. The Stock has managed to achieve an average true range (ATR) of 0.43. Alongside those numbers, its PE Ratio stands at $2.81, and its Beta score is -0.71. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.35. Similarly, its price to free cash flow for trailing twelve months is now 12.57.
In the same vein, AMLX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.70, a figure that is expected to reach -0.00 in the next quarter, and analysts are predicting that it will be -1.32 at the market close of one year from today.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
If we take a close look at the recent performances of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days Average volume was 2.29 million that shows plunge from its year to date volume of 2.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 2.78% While, its Average True Range was 0.27.
Raw Stochastic average of Amylyx Pharmaceuticals Inc (AMLX) in the period of the previous 100 days is set at 0.14%, which indicates a major fall in contrast to 2.67% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.08% that was lower than 281.42% volatility it exhibited in the past 100-days period.
